Final CRISPRMED24 Program - Download pdf.
CRISPRMED24 Abstract Book is now available - Check it here.
- Meet the global CRISPR Medicine/Genomic Medicine community in Copenhagen, Denmark 2024.
- Focus: Tools, Delivery, Safety/Off-target, Diseases, Pre-clinical/clinical, Standards and Regulations | Functional Genomics, Target Identification, Target Validation.
- Segments: University, Hospital, Biotech, Pharma, CRO.
- +400 delegates, +60 speakers confirmed, +100 Posters, 4x Workshops, Network meetings...
- Venue Site: Øksnehallen, Copenhagen, Denmark.
- Organiser: CRISPR Medicine News, CMN.
- Go to the official website here.
If you can not attend CRISPRMED24, make sure to stay updated about the 2nd CRISPR Medicine Conference, CRISPRMED25 - Sign up to the CRISPRMED25 Newsletter.
Keynote Speaker
Luigi Naldini, M.D., Ph.D., is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy (Milan, Italy). He received his medical degree from the University of Turin (Italy) and his PhD from the University “La Sapienza” of Rome (Italy).
For the past 25 years he has pioneered the development and application of lentiviral vectors for gene therapy, which have become one of the most widely used tools in biomedical research and, upon recently entering clinical testing, are providing a long-sought hope of cures for several currently untreatable and otherwise deadly human diseases. Throughout this time, he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, bringing about innovative solutions that are not only being translated into new therapeutic strategies for genetic disease and cancer, but have also yielded novel insights into haematopoietic stem cell function, induction of immunological tolerance, and tumour angiogenesis.
Professor Naldini's work has also contributed to advancing the use of artificial nucleases for targeted genome editing in cell- and gene therapy. To date, he has published over 290 scientific papers, and his SCOPUS Author h-index is 105. He is also co-founder of three innovative biotech start-up companies: Genenta (recently listed on Nasdaq), Epsilen Bio (now acquired by Chroma Medicine) and Genespire.
Scientific Committee
- Karen O´Hanlon Cohrt, Chief Editor CRISPR Medicine News, CMN
- Toni Cathomen, Prof., Director of the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg, Germany
- Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
- Alessia Cavazza, Ass. Prof., Group Leader, University College London's Great Ormond Street Institute of Child Health, England
- Anna Cereseto, Prof., Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy
CRISPRMED24 Speakers
- Dr. André Cohnen, Head of Genomic Medicine, Senior Bayer Science Fellow, Bayer, Germany
- Karina Thorn, Corporate Vice President, PhD, RNA and Gene Therapies, Global Research Technologies, Novo Nordisk, Denmark
- Rasmus O. Bak, Ass. Prof. and Group leader, Aarhus University, Denmark
- Xavier Duportet, CEO and Co-founder, Eligo Bioscience, France
- Toni Cathomen, Prof. and Director of the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg, Germany
- Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
- Dr. Christian Groendahl, CEO and Co-founder, SNIPR Biome, Denmark
- Dr. Pia Johansson, Manager Cell and Gene Therapy Core, Lund University, Sweden
- Avencia Sanchez-Mejias Garcia, CEO and Co-founder, INTEGRA Therapeutics, Spain
- Andre Choulika, CEO, Cellectis, France
- Jan Gorodkin, Prof. and Group leader, University of Copenhagen, Denmark
- Dr. Ayal Hendal, Principal Investigator and Group leader, Bar-Ilan University, Israel
- Dr. Andrew Bellinger, CSO, Verve Therapeutics, US
- Alessia Cavazza, Ass. Prof., Group Leader, Infection, Immunity & Inflammation Department at University College London's Great Ormond Street Institute of Child Health, England
- Yonglun Luo, Professor, Gene and Stem Cell Technology, Aarhus University, Denmark
- Kevin Holden, PhD, Head of Science, Synthego, US
- Dr. Manuel Kaulich, Prof., Goethe University Frankfurt, Germany
- Anna Cereseto, Prof., Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy
- Bernhard Schmierer, Head of Unit, CRISPR Functional Genomics, SciLifeLab and Karolinska Institutet, Stockholm, Sweden
- Dr. Ben P. Kleinstiver, PhD, Assistant Professor at Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, US
- Samantha Maragh, PhD, Leader, Genome Editing Program, National Institute of Standards & Technology (NIST), US
Check the full list of confirmed speakers here
Attending Institutions and Companies (confirmed)
Stay Updated
Official website live.
Stay updated about the program - sign up to the CRISPRMED24 Newsletter.
Interested to learn more about the Sponsorship or Exhibitor Packages?
Few sponsorship packages and exhibitor spaces will be available. Contact us today to learn more.
CRISPRMED24 Sponsors and Supporters
